Senseonics starts first-in-human study of an implantable CGM with no on-body part
Image: Senseonics / Eversense 365 media kit · press-kit
Freedom adds a battery and Bluetooth to the implanted Eversense 365 sensor so it can talk to a phone directly; Senseonics announced the study on 26 October 2026.
Senseonics said on 26 October 2026 that it has started a first-in-human early feasibility study of Freedom, an investigational implantable continuous glucose monitor designed to have no external on-body transmitter.
Freedom builds on the sensing technology of Eversense 365 and adds an integrated battery and embedded Bluetooth, so the implanted sensor communicates directly with a mobile device. It is designed for one year of sensing from a single sensor. The study evaluates clinical safety and device functionality, including that direct Bluetooth link.
Preclinical testing in the second quarter of 2026 ran about seven weeks and logged more than 18,500 communication data points; the company says the preferred design achieved 100% communication success within the target distance. Senseonics expects to start a pivotal study in 2027 and targets a potential commercial launch in 2028. The release gives no participant count or study sites. The image shows the current Eversense 365 sensor, not Freedom.
Sources
- Senseonics Holdings (GlobeNewswire release, via Stock Titan) Primary source
